Compare OUST & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OUST | PHVS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 2020 | 2020 |
| Metric | OUST | PHVS |
|---|---|---|
| Price | $34.32 | $35.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $39.25 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 2.6M | 617.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $169,384,000.00 | N/A |
| Revenue This Year | $33.20 | N/A |
| Revenue Next Year | $37.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 52.46 | N/A |
| 52 Week Low | $16.40 | $20.65 |
| 52 Week High | $63.79 | $38.13 |
| Indicator | OUST | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 47.99 |
| Support Level | $31.95 | $24.73 |
| Resistance Level | $50.62 | $36.80 |
| Average True Range (ATR) | 2.91 | 1.80 |
| MACD | -0.98 | -0.10 |
| Stochastic Oscillator | 2.70 | 36.35 |
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and the Pacific, Europe, the Middle East, and Africa. It derives maximum revenue from the Americas. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensor kits.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.